Management Policies

Message from Leadership

Higher sales in all regions led to record performance.

Sales increased in all regions, thanks to higher reagent sales and taking advantage of growth opportunities in emerging markets

Operating profit grew substantially, as we worked to appropriately control SG&A expenses and benefited from yen depreciation.

Feb. 2025

Kaoru Asano
President

In the first nine months of the fiscal year ending March 31, 2025, sales rose across all regions, as the Sysmex Group benefited from ongoing increases in reagent sales and took advantage of growth opportunities in emerging markets. Operating profit surged as a result of higher gross profit and the impact of yen depreciation. Profit attributable to owners of the parent also increased. Year on year, net sales was up 12.4%, operating profit was up 24.2%, and profit attributable to owners of the parent was up 23.7%. At exchange rates prevailing one year earlier, net sales would have been up 7.8% and operating profit up 5.6%.

Looking at results by business, sales increased in the diagnostics business, centered on the core hematology^*1, hemostasis, urinalysis, and immunochemistry fields. In the mainstay hematology field, reagent sales continued to grow across all regions. Growth was particularly noteworthy in the AP region, where demand for investment in healthcare infrastructure is strong, as instrument and reagent sales both expanded by double digits. In the hemostasis field, sales increased in all regions, with sales of reagents being particularly robust. In the immunochemistry field, sales growth centered on the AP and China region.

In the medical robotics business, we installed an additional seven units in Japan in Q3, as well as three units overseas, in Singapore and Malaysia, bringing cumulative installations to 74 units. The number of cases is rising steadily in Japan and overseas, and we are working steadily to expand business overseas.

Among recent highlights, we were selected for inclusion in the globally prestigious Dow Jones Sustainability World Index, an indicator of ESG investment, for the ninth consecutive year. We also ranked first in the Health Care Equipment & Supplies industry.

In January 2025, we became the first company in the industry^*2 to begin selling cleaning solution packaged in horizontally recycled reagent containers^*3. We are also advancing initiatives aimed at realizing a circular resource value chain in the medical field. We will continue our efforts to achieve a sustainable society and ensure sustainable growth for Sysmex.

I would like to ask our shareholders for your continued support.

【News】

▶Sysmex Selected for the DJSI World Index for the Ninth Consecutive Year
- Achieving the Highest Rank in the Healthcare Equipment & Supplies Industry -

▶Sysmex Becomes the First in the Industry to Launch Reagents Using Horizontally Recycled Containers

*1 Hematology field: The field of in vitro diagnostics that determines whether precise testing is necessary by analyzing the number, type and size of red, white and other blood cells.

*2 Sysmex research

*3 Horizontal recycling:
A recycling method in which used products are re-used as raw materials to manufacture the same type of products again

Back to "Management Policies"